NASDAQ:SUPN Supernus Pharmaceuticals (SUPN) Stock Price, News & Analysis → Everybody laughed when he recommended Netflix (From Stansberry Research) (Ad) Free SUPN Stock Alerts $28.39 -0.38 (-1.32%) (As of 11:13 AM ET) Add Compare Share Share Today's Range$28.30▼$28.7750-Day Range$28.74▼$35.1752-Week Range$21.99▼$35.96Volume168,216 shsAverage Volume404,643 shsMarket Capitalization$1.56 billionP/E RatioN/ADividend YieldN/APrice Target$41.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Supernus Pharmaceuticals alerts: Email Address Supernus Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside44.1% Upside$41.00 Price TargetShort InterestBearish9.16% of Float Sold ShortDividend StrengthN/ASustainability-2.35Upright™ Environmental ScoreNews Sentiment0.34Based on 2 Articles This WeekInsider TradingSelling Shares$1.23 M Sold Last QuarterProj. Earnings Growth26.72%From $1.31 to $1.66 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.63 out of 5 starsMedical Sector247th out of 918 stocksPharmaceutical Preparations Industry105th out of 421 stocks 3.5 Analyst's Opinion Consensus RatingSupernus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageSupernus Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Supernus Pharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted9.16% of the float of Supernus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSupernus Pharmaceuticals has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.Change versus previous monthShort interest in Supernus Pharmaceuticals has recently increased by 2.99%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSupernus Pharmaceuticals does not currently pay a dividend.Dividend GrowthSupernus Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSupernus Pharmaceuticals has received a 58.44% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Topiramate", "Safinamide", "Oxcarbazepine", and "Amantadine" products. See details.Environmental SustainabilityThe Environmental Impact score for Supernus Pharmaceuticals is -2.35. Previous Next 1.3 News and Social Media Coverage News SentimentSupernus Pharmaceuticals has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Supernus Pharmaceuticals this week, compared to 3 articles on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Supernus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,227,433.00 in company stock.Percentage Held by InsidersOnly 8.76% of the stock of Supernus Pharmaceuticals is held by insiders.Read more about Supernus Pharmaceuticals' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Supernus Pharmaceuticals are expected to grow by 26.72% in the coming year, from $1.31 to $1.66 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Supernus Pharmaceuticals is -98.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Supernus Pharmaceuticals is -98.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSupernus Pharmaceuticals has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Supernus Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-up before it’s too late. It’s urgent because it’s what we consider “The #1 Crypto for the AI World.”Learn more about it by watching THIS NOW. About Supernus Pharmaceuticals Stock (NASDAQ:SUPN)Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.Read More SUPN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SUPN Stock News HeadlinesMay 16, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPNMay 10, 2024 | finance.yahoo.comSupernus Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.002 (vs US$0.31 in 1Q 2023)May 10, 2024 | finance.yahoo.comSupernus Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Strategic Shifts and Pipeline ...May 9, 2024 | globenewswire.comSupernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant SeizuresMay 9, 2024 | finance.yahoo.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finance.yahoo.comSupernus Pharmaceuticals Inc (SUPN) Q1 2024 Earnings Call Transcript Highlights: Navigating ...May 8, 2024 | investorplace.comSUPN Stock Earnings: Supernus Pharmaceuticals Misses Revenue for Q1 2024May 8, 2024 | globenewswire.comSupernus Announces First Quarter 2024 Financial ResultsMay 7, 2024 | markets.businessinsider.comSupernus's ADHD Drug Qelbree To Be Commercialized In Latin America By M8 PharmaMay 7, 2024 | prnewswire.comM8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree® (Viloxazine XR) in Latin AmericaMay 6, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPNMay 2, 2024 | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of InvestorsMay 1, 2024 | businesswire.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of InvestorsMay 1, 2024 | globenewswire.comBusy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree StoryApril 29, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of InvestorsApril 28, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPNApril 24, 2024 | globenewswire.comSupernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024April 20, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPNApril 20, 2024 | stockhouse.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPNApril 19, 2024 | nasdaq.comNotable Two Hundred Day Moving Average Cross - SUPNApril 15, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Argenx Se (ARGX), Neogen (NEOG) and Supernus Pharmaceuticals (SUPN)April 10, 2024 | uk.investing.comSupernus receives FDA rejection for Parkinson's treatment, submits additional dataApril 9, 2024 | yahoo.comUS FDA declines to approve Supernus' Parkinson's combination again (April 8)April 8, 2024 | finanznachrichten.deSupernus Pharmaceuticals, Inc.: Supernus Provides Regulatory Update for SPN-830April 8, 2024 | msn.comSupernus stock slides as FDA rejects Parkinson's disease infusion deviceSee More Headlines Receive SUPN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today5/21/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SUPN CUSIP86845910 CIK1356576 Webwww.supernus.com Phone(301) 838-2500Fax301-838-2501Employees652Year FoundedN/APrice Target and Rating Average Stock Price Target$41.00 High Stock Price Target$41.00 Low Stock Price Target$41.00 Potential Upside/Downside+44.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.29) Trailing P/E RatioN/A Forward P/E Ratio21.73 P/E GrowthN/ANet Income$1.32 million Net Margins-2.60% Pretax Margin-1.01% Return on Equity-1.68% Return on Assets-1.20% Debt Debt-to-Equity RatioN/A Current Ratio1.73 Quick Ratio1.49 Sales & Book Value Annual Sales$607.52 million Price / Sales2.58 Cash Flow$1.55 per share Price / Cash Flow18.36 Book Value$16.87 per share Price / Book1.69Miscellaneous Outstanding Shares54,970,000Free Float50,158,000Market Cap$1.56 billion OptionableOptionable Beta1.01 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Jack A. Khattar (Age 63)Founder, President, CEO, Secretary & Director Comp: $1.63MMr. Timothy C. Dec (Age 65)Senior VP & CFO Comp: $635.43kDr. Padmanabh P. Bhatt Ph.D. (Age 67)Chief Scientific Officer & Senior VP of Intellectual Property Comp: $594.14kMr. Frank Mottola (Age 52)Senior Vice President of Quality, GMP Operations & Information Technology Comp: $490.87kDr. Jonathan Rubin M.D. (Age 63)MBA, Senior VP of Research & Development and Chief Medical Officer Comp: $594.65kMr. Kevin T. Anderson (Age 62)Compliance Officer Dr. Todd Horich M.B.A.Ph.D., Senior Vice President of Marketing & Market AccessMr. Taylor RaifordSenior Vice President of SalesDr. Bryan A. Roecklein Ph.D.Senior Vice President of Corporate DevelopmentMs. Tami T. Martin Esq. (Age 69)R.N., Senior Vice President of Regulatory Affairs Comp: $508.5kMore ExecutivesKey CompetitorsPacira BioSciencesNASDAQ:PCRXInnovivaNASDAQ:INVAArcutis BiotherapeuticsNASDAQ:ARQTOcular TherapeutixNASDAQ:OCULORIC PharmaceuticalsNASDAQ:ORICView All CompetitorsInsiders & InstitutionsComerica BankSold 2,380 shares on 5/17/2024Ownership: 0.046%Hancock Whitney CorpBought 5,885 shares on 5/17/2024Ownership: 0.011%Ashford Capital Management Inc.Sold 63,023 shares on 5/16/2024Ownership: 1.389%California State Teachers Retirement SystemSold 2,610 shares on 5/16/2024Ownership: 0.098%Bayesian Capital Management LPBought 6,502 shares on 5/16/2024Ownership: 0.012%View All Insider TransactionsView All Institutional Transactions SUPN Stock Analysis - Frequently Asked Questions Should I buy or sell Supernus Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SUPN shares. View SUPN analyst ratings or view top-rated stocks. What is Supernus Pharmaceuticals' stock price target for 2024? 1 Wall Street analysts have issued 1 year price targets for Supernus Pharmaceuticals' stock. Their SUPN share price targets range from $41.00 to $41.00. On average, they anticipate the company's share price to reach $41.00 in the next twelve months. This suggests a possible upside of 44.1% from the stock's current price. View analysts price targets for SUPN or view top-rated stocks among Wall Street analysts. How have SUPN shares performed in 2024? Supernus Pharmaceuticals' stock was trading at $28.94 on January 1st, 2024. Since then, SUPN shares have decreased by 1.7% and is now trading at $28.46. View the best growth stocks for 2024 here. When is Supernus Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our SUPN earnings forecast. How were Supernus Pharmaceuticals' earnings last quarter? Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) posted its earnings results on Tuesday, February, 27th. The specialty pharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.41 by $0.39. The specialty pharmaceutical company had revenue of $164.30 million for the quarter, compared to the consensus estimate of $155.03 million. Supernus Pharmaceuticals had a negative trailing twelve-month return on equity of 1.68% and a negative net margin of 2.60%. The firm's quarterly revenue was down 1.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.43 EPS. What ETFs hold Supernus Pharmaceuticals' stock? ETFs with the largest weight of Supernus Pharmaceuticals (NASDAQ:SUPN) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), iShares Neuroscience and Healthcare ETF (IBRN), Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Pharmaceuticals ETF (XPH), iShares U.S. Pharmaceuticals ETF (IHE) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).SPDR S&P 600 Small Cap ETF (SLY). What guidance has Supernus Pharmaceuticals issued on next quarter's earnings? Supernus Pharmaceuticals updated its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $580.0 million-$620.0 million, compared to the consensus revenue estimate of $601.5 million. What is Jack A. Khattar's approval rating as Supernus Pharmaceuticals' CEO? 20 employees have rated Supernus Pharmaceuticals Chief Executive Officer Jack A. Khattar on Glassdoor.com. Jack A. Khattar has an approval rating of 81% among the company's employees. What other stocks do shareholders of Supernus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), GW Pharmaceuticals (GWPH), Netflix (NFLX), Corcept Therapeutics (CORT) and Cara Therapeutics (CARA). Who are Supernus Pharmaceuticals' major shareholders? Supernus Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (11.29%), Congress Asset Management Co. MA (1.89%), Ashford Capital Management Inc. (1.39%), Rice Hall James & Associates LLC (0.94%), Price T Rowe Associates Inc. MD (0.81%) and Tributary Capital Management LLC (0.63%). Insiders that own company stock include Frank Mottola, Frederick M Hudson, Jack A Khattar, Padmanabh P Bhatt and Tami Tillotson Martin. View institutional ownership trends. How do I buy shares of Supernus Pharmaceuticals? Shares of SUPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SUPN) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersNext President (Not Trump. Not Biden.)The Freeport SocietyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe #1 Crypto for AIWeiss RatingsDoes this make you sick?Allegiance Gold[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersBill Gates is all about this tiny $2 stockTimothy SykesThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Supernus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.